inVENT-visIOn Study

Integra LifeSciences Corporation42 enrolled

Overview

The objective of the study is to evaluate the safety and efficacy of the Acclarent Tympanostomy Tube Delivery System (TDS) for the placement of Tympanostomy Tube TT(s) under local anesthesia delivered by iontophoresis in an office/clinic setting.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Otitis Media

Interventions

Tympanostomy tube placement (Acclarent iontophoresis device)DEVICE

Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device

Eligibility

Sex: ALLMin age: 6 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Scheduled to undergo tympanostomy tube insertion * At least 6 months old * Behavioral capacity and cooperative temperament to undergo an awake procedure (based on physician judgement) * No history of sensitivity or reaction to anesthesia chosen for the procedure Exclusion Criteria: * Pregnant or lactating females * Significantly atrophic, bimeric, or completely atelectatic tympanic membrane * Otitis externa * Lacerations or abrasions to the external auditory canal or damaged or denuded skin in the auditory canal * Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane * Electrically sensitive subjects and subjects with electrically sensitive support systems (pacemakers, defibrillators, etc.) * Anatomy that precludes sufficient visualization of and access to the tympanic membrane * Anatomy that necessitates tympanostomy tube placement in the posterior half of the tympanic membrane

Locations (1)

South Coast Ear, Nose, & Throat

Port Saint Lucie, Florida, United States

Outcomes

Primary Outcomes

Number of Subjects With Procedural, Serious and Device-related Adverse Events.

Adverse events which are procedural, serious, and device-related.

Time frame: Procedure through 2 weeks post-procedure

Device Success

Device Success is defined as the successful delivery of the tympanostomy tube (TT) across the tympanic membrane (TM) using the Tube Delivery System(TDS). Device Success will be evaluated on a per device basis.

Time frame: Day 0 (day of procedure)

Secondary Outcomes

Procedure Success

Procedure Success is defined as the successful placement of any tympanostomy tube in all enrolled ears in a given subject. Procedure Success is determined on a per subject basis.

Time frame: Day 0 (day of procedure)

Procedure Tolerability

Procedure Tolerability is defined as the proportion of subjects reporting the procedure as tolerable, where tolerable is defined as a score of 0 through 3, using the Wong-Baker FACES pain scale.The Wong-Baker FACES pain scoring system is a scale of 0 to 5, where 0 means 'no hurt', 1 = 'hurts a little bit', 2 = 'hurts little more', 3 = 'hurts even more', 4 = 'hurts whole lot' and 5 = 'hurts worst'. Procedure Tolerability will be determined on a per patient basis, with the patient's score being the average of the scores for the left and right ear if both ears are successfully treated with the Tube Delivery System.

Time frame: Day 0 (day of procedure)

Tube Retention

Tube retention is the presence of a tympanostomy tube placed successfully by the Tula TDS device across the tympanic membrane at the two-week follow-up visit.

Time frame: 2 weeks post-procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.